共 16 条
[1]
Evelopment of fluticasone propionate and comparison with other inhaled corticosteroids. Johnson MD. The Journal of Allergy and Clinical Immunology . 1998
[2]
What’s in a name?Names, definitions, descriptions,and diagnostic criteria of diseases, with emphasis on chronic obstructive pulmonary disease. Snider GL. Respiration . 1995
[3]
Sputum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio in acute asthma. Tanaka H,Miyazaki N,Osahi K,et al. The Journal of Allergy and Clinical Immunology . 2000
[4]
The proteinase-antiproteinase theory of emphysema: a specnlative analyis of recent advances into the pathogeneses of empysema. Knight KR,Burdon JG,Cook L,et al. Respirology . 1997
[5]
Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Grunsvenn PM,Schaych CP,Derenne JP,et al. Thorax . 1999
[6]
Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: ameta-analysis. Grunsven PM,Schaych CP,Derenne JP,et al. Thorax . 1999
[7]
Time to onset of effect of fluticasone propionate in patients with asthma. Szefler SJ,Boushey HA,peramla DS,at al. The Journal of Allergy and Clinical Immunology . 1999
[8]
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Burge PS,Calverley PMA,Jones PW,et al. British Medical Journal . 2000
[9]
Association of chronic mucus hypersecretion with FEV1 decline and COPD morbidity. Vestbo J,Prescott E,Lange P. American Journal of Respiratory and Critical Care Medicine . 1996
[10]
Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Llewellyn Jones CG,Harris TAJ,Stockley RA. American Journal of Respiratory and Critical Care Medicine . 1996